Major Win for AITX's RAD as Multiple ROSA-P 360 Devices to be Deployed in Another Large City
ROSA(TM) Capabilities Leads to Strategic Placement Within City's Iconic Park System
Detroit, Michigan--(Newsfile Corp. - April 15, 2025) - Robotic Assistance Devices Inc. (OTC Pink: AITX) (RAD), a subsidiary of Artificial Intelligence Technology Solutions, Inc., has secured the deployment of two ROSA-P 360 devices through a proactive engagement with a prominent municipal Business Improvement District. The units are being deployed to enhance safety and visibility across key public spaces managed by the local community improvement organization. This strategic placement reflects RAD's growing influence in urban safety initiatives and the rapid adoption of its advanced autonomous security technologies.
Artist's depiction of a RAD ROSA-P 360 mounted on a standard light pole in an urban park setting.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/5243/248480_aitx-rad-rosa-p-large-city-250415-1920x1080.jpg
ROSA-P 360, RAD's portable surveillance platform for public-facing environments, delivers continuous coverage and AI-powered detection across a full 360-degree field of view. Featuring dual ROSA units mounted to a single ground-secured power enclosure, the solution serves as an autonomous deterrent capable of engaging subjects, issuing alerts, and escalating incidents in real time. Its compact footprint, fast deployment capability, and visual presence make it an ideal tool for high-visibility areas where traditional security resources may be limited.
"As someone who has spent decades in law enforcement, I understand the challenges communities face in securing public spaces," said Troy McCanna, Chief Security Officer at RAD and former FBI Special Agent. "Deployments like these show how quickly RAD solutions can step in to support local safety efforts, delivering immediate impact without straining public safety budgets or personnel. It's rewarding to see our technology being embraced by organizations committed to creating safer environments."
The Company anticipates that both devices will be fully deployed and operational within the next two weeks, following final site preparations and coordination with the local stakeholders.
Sitting atop a ROSA-P 360 are two ROSA™ units. ROSA is a multiple award-winning, compact, self-contained security and communication device that can be installed and activated in about 15 minutes. Its AI-driven capabilities include human, firearm, and vehicle detection, license plate recognition, responsive digital signage, audio messaging, and seamless integration with RAD's software suite for real-time notifications and autonomous intelligent responses. Two-way communication is optimized for cellular, including live video from ROSA's high-resolution, full-color, always-on cameras. RAD has published six Case Studies detailing how ROSA has helped eliminate instances of theft, trespassing and loitering at retail centers, hospital campuses, multi-family communities, car rental locations and construction sites across the country.
RAD's ROSA-P 360 is available through the Company's network of authorized dealers and direct sales representatives. This deployment adds to a growing number of RAD units actively supporting public safety efforts in parks, transit zones, business districts, and other high-traffic outdoor spaces across the country. As interest in autonomous security technologies accelerates, RAD continues to deliver practical, effective solutions that address today's evolving security needs.
About Robotic Assistance Devices, Inc. (RAD)Robotic Assistance Devices, Inc. (RAD), a wholly owned subsidiary of Artificial Intelligence Technology Solutions, Inc. (AITX), is a trailblazer in delivering AI-powered autonomous security solutions that transform how organizations protect their facilities and assets. RAD's industry-leading product lineup; including ROSA™, RIO™, AVA™, and RAD Light My Way™ offers cutting-edge security technologies that reduce costs while enhancing operational efficiency. By deploying RAD's AI-fueled systems, organizations can optimize security personnel, improve situational awareness, and achieve superior ROI. RAD's solutions are well-suited for various industries, including municipalities, corporate enterprises, transportation, critical infrastructure, education, and healthcare. Learn more at www.radsecurity.com.
AITX, through its subsidiary, Robotic Assistance Devices, Inc. (RAD), is redefining the nearly $50 billion (US) security and guarding services industry1 through its broad lineup of innovative, AI-driven Solutions-as-a-Service business model. RAD solutions are specifically designed to provide cost savings to businesses of between 35%-80% when compared to the industry's existing and costly manned security guarding and monitoring model. RAD delivers these tremendous cost savings via a suite of stationary and mobile robotic solutions that complement, and at times, directly replace the need for human personnel in environments better suited for machines. All RAD technologies, AI-based analytics and software platforms are developed in-house.
RAD has a prospective sales pipeline of over 35 Fortune 500 companies and numerous other client opportunities. RAD expects to continue to attract new business as it converts its existing sales opportunities into deployed clients generating a recurring revenue stream. Each Fortune 500 client has the potential of making numerous reorders over time.
AITX is an innovator in the delivery of artificial intelligence-based solutions that empower organizations to gain new insight, solve complex challenges and fuel new business ideas. Through its next-generation robotic product offerings, AITX's RAD, RAD-R, RAD-M and RAD-G companies help organizations streamline operations, increase ROI, and strengthen business. AITX technology improves the simplicity and economics of patrolling and guard services and allows experienced personnel to focus on more strategic tasks. Customers augment the capabilities of existing staff and gain higher levels of situational awareness, all at drastically reduced cost. AITX solutions are well suited for use in multiple industries such as enterprises, government, transportation, critical infrastructure, education, and healthcare. To learn more, visit www.aitx.ai, www.radsecurity.com, www.radcam.ai, www.stevereinharz.com, www.radgroup.ai, www.raddog.ai, and www.radlightmyway.com, or follow Steve Reinharz on Twitter @SteveReinharz.
CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTSThe information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Artificial Intelligence Technology Solutions, Inc. (the "Company"). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company's future revenues, results of operations, or stock price.
###
Steve Reinharz949-636-7060@SteveReinharz
1 https://www.ibisworld.com/united-states/market-research-reports/security-services-industry/
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/248480
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
18 minutes ago
- Hamilton Spectator
Treatment.com AI Announces New Medical Education Suite to Enhance Clinical Skills Training Through AI-Simulated Patients
VANCOUVER, BC, June 11, 2025 (GLOBE NEWSWIRE) — AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) ('Treatment') is pleased to announce that it has released its latest version of the Medical Education Suite (MES). The University of Minnesota Medical School has successfully completed a live deployment of AI's new Medical Education Suite (MES), an AI-powered clinical skills assessment platform designed to support medical schools in delivering scalable, rigorous, and cost-effective Objective Structured Clinical Examinations (OSCEs). The deployment, conducted with over 240 third-year medical students, marked the first large-scale implementation of computer-simulated patient cases developed through the Global Library of Medicine (GLM), a clinician-built medical knowledge engine. The exams ran with complete technical reliability during deployment, as well as integrating seamlessly into the school's existing OSCE workflow. 'Our goal is to support medical schools by applying our clinical experience and AI expertise to real educational challenges.' stated Dr. Kevin Peterson, Founder and Chief Medical Officer of AI. 'The Medical Education Suite reflects years of development in diagnostic reasoning and knowledge engineering. By introducing structured, AI-simulated patients alongside live simulated patients, and offering objective real-time scoring, we're helping students build stronger clinical skills in the classroom and giving educators the trusted healthcare education software needed to teach and assess clinical content and behavioral approaches to complex clinical problems with confidence.' The MES is a scalable platform designed to reduce administrative and faculty time, improve objectivity, increase evaluation consistency, and provide a robust digital infrastructure to support both live and AI-simulated formats. The focus of the platform is to help enhance the clinical skills of our next generation of healthcare professionals. By incorporating curated AI-generated cases and the supportive services provided by Treatment, the system enables: 'Partnering with AI gave us the opportunity to explore how clinically governed AI can strengthen the way we assess and support student learning. The MES allowed us to deliver a high-stakes OSCE at scale, while ensuring consistent, objective evaluation aligned with our academic standards. The MES represents a meaningful step forward in the evolution of medical education.' said Professor Claudio Violato, Assistant Dean, University of Minnesota Medical School. 'We look forward to sharing our findings.' The MES combines AI-simulated patients with automated feedback, helping faculty assess diagnostic and management reasoning, clinical prioritization, and documentation quality, all mapped to learning objectives. Early feedback suggests that the platform enhances the student learning experience and strengthens the reliability of OSCE results. Preliminary results of the accuracy and precision of the GLM as applied in the MES platform were presented at the AAMC's 2025 Group on Information Resources meeting. Prof. Violato, Dr. Peterson, and their respective teams are preparing further scientific publications detailing the methodology, deployment, and outcomes of the UMN program. AI is engaging with a wide variety of other schools, with the goal to extend the MES offering across North America, the UK, and to other international OSCE markets. About AI Inc. AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, AI has built a comprehensive, personalized healthcare AI engine — the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. AI's GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. Learn more at: or contact . About University of Minnesota Medical School Founded in 1888, the University of Minnesota Medical School is one of the nation's largest, with three campuses in Minneapolis, Duluth, and St. Cloud. It enrolls first- and second-year students at Duluth and St. Cloud, and carries clinical training at the Twin Cities campus and affiliated hospitals. The school educates future physicians through MD, graduate, undergraduate, and continuing professional development programs, supported by over 3,000 faculty members and 20+ research centers and institutes. Its core mission is to improve health through exceptional education, compassionate patient care, and leading-edge biomedical research, particularly focusing on primary care, specialty medicine, rural communities, and American Indian/Alaska Native populations. The school is nationally recognized for its NIH-funded research (ranked #21 overall, #2 among public medical schools) and emphasizes interprofessional, community-based training while promoting equity and access across diverse populations. Learn more at: FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO – AI Inc. Email: Media inquiries: Sales: Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statement This news release contains forward-looking statements that are based on AI's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although AI believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Business Wire
35 minutes ago
- Business Wire
Aera Technology Advances People-Centric Decision Intelligence with Agentic AI
LONDON--(BUSINESS WIRE)--Today at AeraHUB 25 London, the premier decision intelligence summit, Aera Technology will announce a major release of its industry-leading Aera Decision Cloud™, introducing a new wave of Agentic AI capabilities that empower users across roles and experience levels to harness AI to make smarter, faster decisions at scale. 'Aera Decision Cloud is the only platform that unifies the full decision-making context — blending structured and unstructured enterprise data, human expertise, and the reasoning capabilities of large language models." Fred Laluyaux, CEO, Aera Technology Share With this release, Aera Technology expands the frontier of people-centric decision intelligence. From the frontlines to the back office, any users can now tap the power of agents to build Aera Skills™ decision logic with natural language prompting — expanding decision-making use cases and unlocking value. A new AI-powered Data Wizard also allows data to be uploaded and categorized in seconds, and an enhanced Aera Chat interface delivers real-time insights, bringing the power of AI-driven decision-making directly into users' hands. 'Aera Decision Cloud is the only platform that unifies the full decision-making context — blending structured and unstructured enterprise data, human expertise, and the reasoning capabilities of large language models,' said Fred Laluyaux, Co-Founder, President, and CEO of Aera Technology. 'By putting these advanced capabilities directly in the hands of users, we're helping organizations achieve new levels of speed and agility in an increasingly complex world.' Meeting the Moment: AI for Today's Enterprise Challenges This comes at a pivotal time, when the speed and precision of decision execution can determine business success — and organizations face ongoing talent shortages, reskilling needs and increasing pressure to achieve tangible outcomes using AI technologies. Aera Technology's latest release redefines how decisions are made. By placing humans — regardless of technical expertise — at the center of creating AI-powered decision flows, Aera enables a shift from people doing data analysis to people architecting decision automation and overseeing action. This shift empowers business experts to increase their productivity and strategic impact. Key Innovations Rapid Skill Creation: Build Aera Skills™ with embedded AI agents that reason and act based on natural language instructions with built-in guardrails that ensure transparency, accountability, and governance. Any Data, Any Format: Tap into both structured and unstructured data sources — from transactional systems to PDFs and emails — to inform context-rich decisions. Enhanced Aera Cha t: Ask complex, data-driven questions in natural language and receive precise, actionable answers — with execution capabilities built directly into the chat. Smart Data Wizard: Upload data in seconds. The Data Wizard automatically classifies and prepares it for use — no technical training required. Key Benefits Data-Ready from Any Source: Seamlessly integrates structured and unstructured data — from systems, documents, and emails — to automate complex processes like claims management, procurement negotiations, and contract compliance. From Coding to Prompting: Accelerates time to value by defining decision intent in natural language. Agentic AI handles reasoning and generates decision logic. Autonomous, Scalable Collaboration: Communicates and coordinates across people, systems, and vendors, automating decision processes, such as negotiating order modifications. Fast Time to Action: Detects decision triggers, simulates alternatives, and executes actions autonomously. Join Us and See it in Action AeraHUB 25 London: The Decision Intelligence Summit June 11, 2025 | The Brewery, 52 Chiswell Street, London View the session lineup Learn more about Aera agentic decision intelligence Follow Aera Technology on LinkedIn for live updates and insights from the event. About Aera Technology Aera Technology, the decision intelligence company, created Aera, the first decision intelligence agent. Real-time and always-on, Aera understands how a business works, makes actionable recommendations, predicts business outcomes, executes decisions at scale, and learns from every decision. Supporting the full spectrum of decisions, from operational to strategic, Aera is powered by Aera Decision Cloud™ and its composable Aera Skills™. By empowering the world's leading companies to optimize decisions across the value chain, Aera is enabling a more sustainable, intelligent, and efficient world. Learn more at
Yahoo
2 hours ago
- Yahoo
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines ROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, and Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, today announced a strategic collaboration aimed at enhancing efficiency, scalability, and productivity in cell therapy manufacturing. This collaboration combines the MaxCyte ExPERT™ platform and proven Flow Electroporation® technology, widely recognized for its efficient and scalable transfection capabilities, utilized in over 19 active clinical and commercial programs, with Ori's innovative next-generation cell therapy manufacturing platform, IRO® (ee-RO). The collaboration will specifically evaluate how the IRO platform can optimize the yield and streamline the manufacturing timelines of MaxCyte-engineered primary T cells compared to traditional post-electroporation cell expansion processes. As a key component of this joint effort, Ori and MaxCyte have selected CD19 CAR expression via CRISPR knock-in in activated T cells as the test system for initial evaluation. MaxCyte's technology offers unparalleled flexibility and efficiency in transfecting cells at clinical scale, seamlessly integrating with diverse upstream and downstream processes within cell therapy workflows. The IRO platform complements this by introducing automated fluid handling, customizable mixing, and the OriConnect® tubeless sterile connection system, enhancing cell culture efficiency and scalability. Together, these complementary technologies provide therapy developers with a powerful toolkit to achieve clinically relevant quantities of gene-edited T cells more rapidly and efficiently. Maher Masoud, President and CEO of MaxCyte, commented, 'We are excited to collaborate with the team at Ori Biotech, combining our respective strengths and innovative technologies to significantly enhance manufacturing processes. This partnership underscores our commitment to enabling therapy developers to more effectively address the evolving demands of cell therapy manufacturing, ultimately accelerating the availability of transformative treatments for patients.''Our partnership with MaxCyte is another example of Ori's dedication to providing flexible and scalable solutions that address critical challenges in cell and gene therapy manufacturing,' said Jason C. Foster, CEO of Ori Biotech. 'By integrating modular, best-of-breed technologies, we're raising the standard of manufacturing by enhancing commercial viability. Ultimately, this collaboration helps bring cell therapies to patients faster, more reliably, and at greater scale.' Through their shared commitment to innovation and industry collaboration, MaxCyte and Ori Biotech are enabling developers of advanced therapies to adopt integrated, best-of-breed solutions, accelerating the path from research to commercialization and making next-generation treatments more accessible to patients globally. About MaxCyte At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at and follow us on X and LinkedIn. About Ori Biotech Ori Biotech is a London and Philadelphia-based manufacturing technology company on a mission to enable widespread patient access to life-saving cell and gene therapies. IRO®, Ori's next-generation manufacturing platform automates better biology, accelerates product development and enables therapy developers to scale their products' clinical and commercial impact by seamlessly transitioning from R&D to GMP on one platform. The promise of the innovative Ori platform is to automate cell therapy manufacturing, increasing throughput, improving quality and decreasing costs by combining proprietary hardware, consumables, software, data and analytics. For news and updates, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated benefits, outcomes, and impact of the collaboration between MaxCyte and Ori Biotech; the potential for improving clinical success and commercial viability through new manufacturing standards; and the intention to accelerate development timelines, increase access to next-generation cell therapies, and deliver transformative treatments to patients globally. These statements are based on current expectations, estimates, forecasts, and projections about the industry and markets in which MaxCyte operates, as well as management's current beliefs and assumptions. Words such as 'aims,' 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' 'may,' 'will,' 'should,' 'continue,' and variations of such words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions that are difficult to predict and are often beyond the control of the companies involved. Actual outcomes and results may differ materially from those expressed or implied in these forward-looking statements due to various factors, including changes in market conditions, technological advancements, regulatory developments, and the success of ongoing research and evaluation efforts. Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended May 8, 2025. These documents are available through the Investor Menu, Financials section, under 'SEC Filings' on the Investors page of our website at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, MaxCyte does not undertake any obligation to update or revise any forward-looking statements to reflect new information, events, or circumstances after the date of this release. MaxCyte Contacts: US IR AdviserGilmartin GroupDavid Deuchler, CFA+1 415-937-5400ir@ Oak Street CommunicationsKristen Whitekristen@ Nominated Adviser and Joint Corporate BrokerPanmure LiberumEmma Earl / Freddy CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500 UK IR AdviserICR HealthcareMary-Jane ElliottChris Welsh+44 (0)203 709 5700maxcyte@ Ori Biotech Contact: Debby Betzmedia@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
